📚 Insights into #immunotherapy – recently published in Neuro-Oncology: Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study
👉 doi.org/10.1007/s110...
#EANOessentials #NeuroOncology #Pembrolizumab

Keytruda R&D costs Keytruda, manufactured by the US pharmaceutical giant Merck Sharp & Dohme (MSD), offers genuine hope for cancer patients and oncologists alike. However, it’s also a nightmare for insurers and public h...

In this context @publiceye.ch also shared with @icij.org an exclusive estimate of MSD's R&D costs for #pembrolizumab, based on independent verifiable data. This represents just a tiny fraction of what MSD pretends having invested - $1.9bn vs >$30bn. Check it out here www.publiceye.ch/en/topics/ph...

Pharmaindustrie: Profit mit öffentlichen Mitteln - Gute Pillen - Schlechte Pillen Die Pharmaindustrie begründet die enormen Preise für Arzneimittel mit eigenen hohen Forschungskosten. Doch oft zahlt die Gesellschaft doppelt.

Das Beispiel des #Krebsmedikaments #Keytruda (Wirkstoff #Pembrolizumab) verdeutlicht, dass die hohen Forschungskosten, mit denen die Pharmaindustrie hohe Preise begründet, oft nur vorgeschoben sind

Die Gesellschaft zahlt doppelt

gutepillen-schlechtepillen.de/pharmaindust...
1/3

Teures Krebsmedikament: Wie Keytruda zum Systemsprenger wird Keytruda: Die Gesundheitskosten für das Krebsmittel kletterten in Deutschland allein im letzten Jahr auf mehr als zwei Milliarden Euro.

Müssen #Krebsmedikamente so teuer sein?

Eine aktuelle Recherche von #ZDFfrontal @spiegel.de @derstandard.at und @icij.org zeigt am Beispiel des Krebsmedikaments #Keytruda (Wirkstoff #Pembrolizumab), wie hoch die Gewinne des Herstellers sind.

www.zdfheute.de/politik/deut...

1/3

Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non–Small Cell Lung Cancer: Insights From a National Real-World Cohort | JCO Oncology Practice PURPOSEPembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), is a standard first-line treatment for advanced non–small cell lung cancer (NSCLC). Although fixed-dose pembrolizumab (200 mg once every...

Protocolo a dosis fija de pembrolizumab es comparable al basado en el peso en pac c/CA pulmón no microcítico, protocolo basado en el peso puede ser coste-efectiva en pacientes c/peso bajo y en situaciones con recursos limitado #pembrolizumab #dosification ascopubs.org/doi/abs/10.1...

Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall survival (OS), and objective response r...

#Lenvatinib plus #pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 jitc.bmj.com/content/14/2...

#clinicaltrial #endometrialcancer

Citius Oncology's Encouraging Phase 1 Study Results for LYMPHIR and Pembrolizumab in Gynecologic Cancer Citius Oncology announced positive results from a Phase 1 trial of LYMPHIR used with pembrolizumab for treating difficult gynecologic cancers. These findings show promise for future therapies.

Citius Oncology's Encouraging Phase 1 Study Results for LYMPHIR and Pembrolizumab in Gynecologic Cancer #USA #Cranford #LYMPHIR #Citius_Oncology #Pembrolizumab

📌 En este póster destacamos 5 medicamentos clave que se utilizan con frecuencia en la práctica clínica.

#CancerDePulmon #Inmunoterapia #TerapiaDirigida #Quimioterapia #InnovacionMedica #Pembrolizumab #Osimertinib #Alectinib #Pemetrexed #DengYueMedicinasEnHongKong

This is big news. As a scientist and ovarian cancer researcher, I know that platinum resistant ovarian cancer is a bear to treat. A major advance in the field of #ovariancancer. Let's keep it up and find more options for these women. #Keytruda #immunotherapy #pembrolizumab

アステラス、PADCEV＋Keytruda周術期療法を日本でsNDA提出──シスプラチン不適格MIBCでEV-303/KEYNOTE-905に基づく | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

Astellas submits sNDA in Japan for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) as perioperative therapy in cisplatin-ineligible MIBC

stellanews.life/technology/8...

#BladderCancer #MIBC #EnfortumabVedotin #Pembrolizumab #EV303 #KEYNOTE905 #sNDA

Tumori, via libera al pembrolizumab per 3 nuove indicazioni terapeutiche ROMA (ITALPRESS) – Negli ultimi 10 anni, in Italia, i decessi per cancro sono diminuiti del 9%. Un risultato importante, a cui hanno contribuito le campagne di prevenzione, l’adesione agli screening e l’innovazione ...

È ACCADUTO IERI: Tumori, via libera al pembrolizumab per 3 nuove indicazioni terapeutiche ... LEGGI TUTTO #tumori #cancro #pembrolizumab #salute #prevenzione

Tumori, via libera al pembrolizumab per 3 nuove indicazioni terapeutiche ROMA (ITALPRESS) – Negli ultimi 10 anni, in Italia, i decessi per cancro sono diminuiti del 9%. Un risultato importante, a cui hanno contribuito le campagne di prevenzione, l’adesione agli screening e l’innovazione ...

Tumori, via libera al pembrolizumab per 3 nuove indicazioni terapeutiche ... LEGGI TUTTO #Tumori #Cancro #Salute #Prevenzione #Pembrolizumab

This large-scale PALACE-2 trial shows that preoperative #pembrolizumab plus #chemoradiotherapy in resectable #ESCC achieved a 43.2% pCR rate, acceptable safety, and one‑year survival over 90%, with #IL6 identified as a predictive #biomarker.

#OpenAccess in #STTT: doi.org/10.1038/s413...

DRAGON Trial: Linavonkibart + Pembrolizumab in PD-1–Resistant Solid Tumors - OncoDaily DRAGON trial linavonkibart pembrolizumab shows feasible safety and responses after PD-1 resistance, strongest in ccRCC with biomarker-linked activity.

DRAGON Trial: Linavonkibart + Pembrolizumab in PD-1–Resistant Solid Tumors

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DRAGON #Linavonkibart #Pembrolizumab

Kelun-Biotech's Sacituzumab Tirumotecan Receives Breakthrough Therapy Status in China for NSCLC Treatment Kelun-Biotech recently secured Breakthrough Therapy Designation for Sacituzumab Tirumotecan combined with Pembrolizumab, targeting NSCLC treatment in China.

Kelun-Biotech's Sacituzumab Tirumotecan Receives Breakthrough Therapy Status in China for NSCLC Treatment #China #Chengdu #Kelun-Biotech #Pembrolizumab #sacituzumab_tirumotecan

PLANeT Trial: Low-Dose Pembrolizumab Plus Neoadjuvant Chemotherapy in Localized TNBC - OncoDaily PLANeT Trial evaluates low-dose pembrolizumab with neoadjuvant chemotherapy, improving pCR in TNBC while reducing cost and toxicity.

PLANeT Trial: Low-Dose Pembrolizumab Plus Neoadjuvant Chemotherapy in Localized TNBC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PLANeT #Pembrolizumab #TNBC #BreastCancer

Sacituzumab Govitecan + Pembrolizumab in mNSCLC Sacituzumab govitecan combined with pembrolizumab shows promising efficacy and manageable safety in first-line metastatic NSCLC.

Sacituzumab Govitecan Plus Pembrolizumab as First-Line Therapy in mNSCLC: EVOKE-02 Study

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SacituzumabGovitecan #Pembrolizumab #mNSCLC #NSCLC #EVOKE-02

Preoperative #pembrolizumab plus #chemoradiotherapy in resectable #EsophagealSquamousCellCarcinoma achieves a 43.2% pCR and shows acceptable safety with strong 1-year survival. #IL6 was identified as a key predictive #biomarker. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

KEYTRUDA皮下投与型がEUで承認、がん治療で初の1分投与可能な免疫チェックポイント阻害薬 | STELLANEWS.LIFE メルクのKEYTRUDA（ペムブロリズマブ）皮下投与型が欧州委員会により承認。従来の点滴型に比べ、最短1分での投与が可能となり、がん患者の治療選択肢が拡大。

Keytruda SC approved in the EU — the first checkpoint inhibitor enabling 1-minute subcutaneous dosing.

🔗 Full article: stellanews.life/technology_c...

#Keytruda #MSD #Merck #Pembrolizumab #ImmunoOncology #CheckpointInhibitor #Subcutaneous #CancerTreatment #Oncology #Innovation

【KEYTRUDA皮下投与型がEUで承認】
メルク（MSD）は、ペムブロリズマブ製剤「KEYTRUDA（キイトルーダ）」の皮下投与型（Keytruda SC）が、
欧州連合で成人の全適応に対して承認されたと発表。

#MSD #Merck #Keytruda #キイトルーダ #がん免疫療法 #皮下投与 #欧州承認 #Pembrolizumab #免疫チェックポイント阻害薬 #がん治療

From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.

Watch the full interview 👉 buff.ly/RNdTu6h

#OncSky #MedNews

Krebsmedikament: Wie man mit einem Trick die Preise hochhält - Gute Pillen - Schlechte Pillen Mit Pembrolizumab verdient die Pharmafirma MSD viel Geld. Damit das auch so bleibt, lässt sich der Hersteller einiges einfallen.

#Krebs-Behandlung: 2028 läuft das Patent für #Pembrolizumab aus, dann droht Konkurrenz. Doch die Firma hat sich etwas einfallen lassen: Sie entwickelte eine neue Darreichungsform. Statt einer ­Infusion wird der Wirkstoff unter die Haut gespritzt💉💰💰💰

Eisai Showcases Advancements in Endometrial Cancer Treatments at IGCS 2025 Eisai presents new findings on endometrial cancer care, featuring pivotal data on lenvatinib and pembrolizumab at IGCS 2025.

Eisai Showcases Advancements in Endometrial Cancer Treatments at IGCS 2025 #United_States #Eisai #Nutley #Pembrolizumab #Lenvatinib

Evolution Trial Evaluates Radiotherapy-Free Chemoimmunotherapy with Pembrolizumab in Locally Advanced NSCLC with High PD-L1 Expression

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Evolution #Chemoimmunotherapy #Pembrolizumab #NSCLC

#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery

🧬 Molecule of the Moment: #mRNA4359 + #pembrolizumab
At #ESMO2025, #Moderna reported early Phase 1/2 data showing mRNA-4359 may overcome checkpoint inhibitor–resistant #melanoma by targeting #PDL1 & #IDO1 pathways. Combo with pembrolizumab showed manageable safety, no new immune AEs.

Promising Results of Post-Surgery Immunotherapy for Rare Skin Cancer A recent study reveals the effectiveness of immunotherapy in preventing aggressive skin cancer from spreading post-surgery, offering hope to affected patients.

Promising Results of Post-Surgery Immunotherapy for Rare Skin Cancer #United_States #New_York #Pembrolizumab #NYU_Langone_Health #Merkel_Cell_Carcinoma

HERCULES Trial Shows Pembrolizumab Plus Platinum Chemotherapy Improves Outcomes in Advanced Penile Cancer - OncoDaily The HERCULES trial shows pembrolizumab plus platinum chemotherapy achieves meaningful survival benefit in advanced penile cancer with manageable safety.

HERCULES Trial Shows Pembrolizumab Plus Platinum Chemotherapy Improves Outcomes in Advanced Penile Cancer

oncodaily.com/new-paper-al...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HERCULES #Pembrolizumab #PenileCancer

Eisai Showcases Groundbreaking Oncology Research at ESMO 2025 with Long-Term Survival Data Eisai is set to highlight its innovative oncology research at ESMO 2025, presenting pivotal findings including 5-year survival data from Study 309/KEYNOTE-775.

Eisai Showcases Groundbreaking Oncology Research at ESMO 2025 with Long-Term Survival Data #United_States #Eisai #Nutley #Pembrolizumab #Lenvatinib